Salmeterol: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Beta-2 agonist, bronchodilator *Dosage Forms: *Routes of Administration: Inhalation *Common Trade Names: ==Adult Dosing== *1 oral inhalation (5...") |
ClaireLewis (talk | contribs) |
||
| Line 38: | Line 38: | ||
==See Also== | ==See Also== | ||
*[[Beta-2 | *[[Beta-2 agonist]] | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revision as of 21:21, 7 November 2016
Administration
- Type: Beta-2 agonist, bronchodilator
- Dosage Forms:
- Routes of Administration: Inhalation
- Common Trade Names:
Adult Dosing
- 1 oral inhalation (50mcg) q12h
Pediatric Dosing
- >4yo: 1 oral inhalation (50mcg) q12h
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Severe asthma exacerbation, asthma-related death
- Prolonged QT interval
Common
- Musculoskeletal pain
- Headache
Pharmacology
- Half-life: 5.5h
- Metabolism: Hepatic
- Excretion: Mostly fecal
Mechanism of Action
- Long-acting beta-2 agonist, stimulates adenyl cyclase--> increased levels of cyclic AMP--> bronchial smooth muscle relaxation